超声引导PMCT联合阿帕替尼治疗转移性肝癌的临床评价

Effects of ultrasound-guided PMCT combined with apatinib in treatment of metastatic liver cancer

目的观察超声引导经皮肝穿刺微波热凝肝癌损毁术(PMCT)联合阿帕替尼治疗转移性肝癌的临床疗效及安全性。方法选取在医院接受治疗的转移性肝癌患者42例,分为观察组和对照组,各21例。对照组接受PMCT治疗,观察组接受PMCT联合阿帕替尼治疗。比较两组的临床疗效及安全性,于术前及术后1个月检测两组血清血管内皮生长因子(VEGF)和基质金属蛋白酶-9(MMP-9)的水平。结果术后1个月,两组血清VEGF和MMP-9的含量较治疗前均降低(P<0.05),且观察组显著低于对照组(P<0.05)。观察组术后1个月疾病控制率以及术后3和6个月生存率均高于对照组,但组间差异无统计学意义(P>0.05)。结论超声引导PMCT治疗转移性肝癌安全、有效,联合阿帕替尼可能在控制疾病进程及延长患者生存周期方面具有积极的作用,其作用机制可能与阿帕替尼抑制肿瘤新生血管生成有关。

Objective To observe the effects and safety of ultrasound-guided percutaneous microwave coagulation therapy（PMCT） combined ＂with apatinib in the treatment of metastatic liver cancer. MeAods A total of 42 patients ＂with metastatic liver cancer to receive treatment in our hospital were selected and divided into an observation group and a control group （n =21, respectively）. The control group was treated with PMCT and the observation group with PMCT combined with apatinib. The effects and safety between the two groups were compared. The levels of serum vascular endothelial growth factor （VEGF） and matrix metalloproteinase-9 （MMP-9） in the two groups were detected one month before and after the operation. Results One month after the operation, the contents of the serum VEGF and MMP-9 in the two groups decreased （P 〈 0.05）, and the contents in the observation group were significantly lower than those in the control group （P 〈 0.05）. The disease control rate one month after the operation and the postoperative three-and six-month survival rates in the observation group were higher than those in the control group, but there was no statistical difference between the two groups （P〉 0.05）. Collusion Ultrasound-guided PMCT is safe and effective in the treatment of metastatic liver cancer. The combination with apatinib may have positive effects in controlling the disease progression and prolonging the patients＇ life cycle. The mechanism of action may be related to apatinib＇s inhibition of tumor angiogenesis.